Government · 9 deals
Every published round CUREator+ took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted, and a place in one of its own programs is under Cohorts.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| WeGuide | Grant | 12 Aug 2026 | $1.9m | Lead | Dealroom (21 Aug 2026), Dealroom (13 Aug 2026) | |
| Neurotologix | Grant | 12 Aug 2026 | $2m | Lead | Dealroom (21 Aug 2026), Dealroom (13 Aug 2026) | |
| Navier Medical Ltd | Grant | 12 Aug 2026 | $2.1m | Lead | Dealroom (21 Aug 2026), Dealroom (13 Aug 2026) | |
| Luma Bio | Grant | 12 Aug 2026 | $2.5m | Lead | Dealroom (21 Aug 2026), Dealroom (13 Aug 2026) | |
| Frontier Inflammasome Therapeutics | Grant | 12 Aug 2026 | $2.5m | Lead | Dealroom (21 Aug 2026), Dealroom (13 Aug 2026) | |
| Aleris Therapeutics | Grant | 12 Aug 2026 | $2.5m | Lead | Dealroom (21 Aug 2026), Dealroom (13 Aug 2026) | |
| TasTest | Grant | 23 Sep 2026 | $2.5m | Participant | This Week in Australian Startups, Startup Daily | |
| Kinoxis Therapeutics | Grant | 23 Sep 2026 | $2.5m | Participant | Dynamic Business, Uniseed, Dealroom, Startup Daily (23 Sep 2026), Startup Daily (23 Sep 2026) | |
| CodeBreakers | Grant | 23 Sep 2026 | $2.1m | Participant | This Week in Australian Startups, Startup Daily |
Everyone CUREator+ has named to a program in published coverage. A place in a program is not a raise: the cheque is the figure recorded with the place, which is the program's standard terms where we hold them, and a blank is one we don't.
| Member | Program | Announced | Cheque | Sources |
|---|---|---|---|---|
| Aleris Therapeutics | CUREator+ | 13 Aug 2026 | - | - |
| Frontier Inflammasome Therapeutics | CUREator+ | 13 Aug 2026 | - | - |
| Luma Bio | CUREator+ | 13 Aug 2026 | - | - |
| Navier Medical Ltd | CUREator+ | 13 Aug 2026 | - | - |
| Neurotologix | CUREator+ | 13 Aug 2026 | - | - |
| WeGuide | CUREator+ | 13 Aug 2026 | - | - |
Companies CUREator+ has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Aleris Therapeutics | 12 Aug 2026, Grant | 2 | 2 | |
| CodeBreakers | 23 Sep 2026, Grant | 1 | 0 | |
| Frontier Inflammasome Therapeutics | 12 Aug 2026, Grant | 2 | 2 | |
| Kinoxis Therapeutics | A clinical candidate that aims to provide an alternative to antipsychotics for managing a… | 23 Sep 2026, Grant | 1 | 0 |
| Luma Bio | 12 Aug 2026, Grant | 2 | 2 | |
| Navier Medical Ltd | 12 Aug 2026, Grant | 2 | 2 | |
| Neurotologix | 12 Aug 2026, Grant | 2 | 2 | |
| TasTest | 23 Sep 2026, Grant | 1 | 0 | |
| WeGuide | 12 Aug 2026, Grant | 2 | 2 |
Fund closes reported for CUREator+, as distinct from the investments it has made.
Companies CUREator+ has backed that another company then bought. An exit for the holding, not a deal CUREator+ did.
| Name | Role | Sources |
|---|---|---|
| Dr Amanda Vrselja | Program Head | Startup Daily |
Stories naming CUREator+. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Seven Australian health startups receive equity-free grants totalling $15.6 million in the second CUREator+ round for dementia research, backed by the Medical Research Future Fund, spanning gene editing, medicines and diagnostic tools.
Six Australian health tech startups received non-dilutive grants totaling $13.5 million from the government-backed CUREator+ program to accelerate commercialisation of medical innovations.
Six Australian biomedical and health ventures receive a combined $13.5 million in non-dilutive grants through round two of the CUREator+ commercialisation program operated by Brandon BioCatalyst and backed by the Medical Research Future Fund.
Also Dealroom
Six Australian health tech startups received a combined $13.5 million in non-dilutive funding from the CUREator+ program, supported by the Australian Government.
CUREator+ granted thirteen point five million dollars in non-dilutive funding to six Australian health tech startups to support commercialisation of medical innovations.
Government-backed CUREator+ program awards non-dilutive funding to seven Australian companies developing dementia and cognitive decline therapeutics, devices and digital health tools.
CUREator+, backed by Brandon BioCatalyst, ANDHealth and Dementia Australia, launches second round offering non-dilutive funding to startups targeting dementia and cognitive decline.
Eight Australian health startups received equity-free grants totaling 18.5 million dollars from the CUREator+ program, supported by government funding and delivered with partners Brandon BioCatalyst and ANDHealth.
Index of the venture firm's portfolio updates: financing rounds for AdvanCell and ENA Respiratory, grant awards via incubator programs, two closes of Fund Six, board hires, and Myricx Bio's completed sale to Novartis.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Uniseed·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon Capital portfolio·SmartCompany·AFR Technology·Startup Daily·Startup Daily·SmartCompany·Startup Daily·Startup Daily·@AuManufacturing·finance.yahoo.com·enarespiratory.com·Mirage News·advancell.com.au·Forbes Australia·datapile.co·Dealroom·Forbes Australia·datapile.co·Biotech Dispatch·fundedstartupsdaily.com·fundedstartupsdaily.com